Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale

Resumen detallado

Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with…

Phase 2 results showed EloraTZP, an investigational combination of eloralintide and tirzepatide, delivered substantial weight loss and A1C improvements in participants with obesity and type 2 diabetes

Results from TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 demonstrated retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity and knee osteoarthritis pain in adults with obesity

People reported Foundayo was simple and easy to use in a new real-world evidence study, while patient-reported outcomes showed that participants treated with eloralintide reported reductions in food noise, food cravings and alcohol consumption

INDIANAPOLIS, Nov. 14, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), will present new data across its cardiometabolic health portfolio at ObesityWeek 2026, taking place November 14 to 17, 2026, in Washington, D.C. The presentations span clinical trial results, patient-reported outcomes and real-world evidence and reflect Lilly's commitment to advancing potential treatment options that address health outcomes, day-to-day experiences and the diverse needs of people living with complex chronic diseases.

Kenneth Custer, Ph.D., Executive Vice President and President of Lilly Cardiometabolic Health: "Obesity care is about more than numbers on the scale: it is about improving overall health and addressing the myriad of ways the disease can affect daily life, through treatment options that meet different needs. At ObesityWeek 2026, new evidence across our portfolio reflects a broader view of care, including clinical outcomes for varied populations and obesity-related conditions, as well as the treatment experience for people who take these medicines. Together, these data reinforce how Lilly has helped to transform obesity care and continues to advance next-generation treatment options."

EloraTZP Phase 2 oral session | Sunday, November 15, 2026 | 3:30 to 4:30 p.m.

Retatrut…

Inicio del artículo, extracto de PR Newswire. Para leer el resto, abra el artículo en el sitio del medio.